186 related articles for article (PubMed ID: 32358810)
1. The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour.
Westerdijk K; Krens SD; van der Graaf WTA; Mulder SF; van Herpen CML; Smilde T; van Erp NP; Desar IME
Br J Clin Pharmacol; 2021 Feb; 87(2):326-335. PubMed ID: 32358810
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Drug Monitoring of Sunitinib in Gastrointestinal Stromal Tumors and Metastatic Renal Cell Carcinoma in Adults-A Review.
Demlová R; Turjap M; Peš O; Kostolanská K; Juřica J
Ther Drug Monit; 2020 Feb; 42(1):20-32. PubMed ID: 31259881
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma.
Noda S; Otsuji T; Baba M; Yoshida T; Kageyama S; Okamoto K; Okada Y; Kawauchi A; Onishi H; Hira D; Morita SY; Terada T
Clin Genitourin Cancer; 2015 Aug; 13(4):350-358. PubMed ID: 25701374
[TBL] [Abstract][Full Text] [Related]
5. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.
Theou-Anton N; Faivre S; Dreyer C; Raymond E
Drug Saf; 2009; 32(9):717-34. PubMed ID: 19670913
[TBL] [Abstract][Full Text] [Related]
6. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.
Cabel L; Blanchet B; Thomas-Schoemann A; Huillard O; Bellesoeur A; Cessot A; Giroux J; Boudou-Rouquette P; Coriat R; Vidal M; Saidu NEB; Golmard L; Alexandre J; Goldwasser F
Fundam Clin Pharmacol; 2018 Feb; 32(1):98-107. PubMed ID: 29055166
[TBL] [Abstract][Full Text] [Related]
7. Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.
Sabanathan D; Zhang A; Fox P; Coulter S; Gebski V; Balakrishnar B; Chan M; Liddle C; Gurney H
Cancer Chemother Pharmacol; 2017 Aug; 80(2):385-393. PubMed ID: 28667354
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib.
Deeks ED; Keating GM
Drugs; 2006; 66(17):2255-66; discussion 2267-8. PubMed ID: 17137406
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib in solid tumors.
Gan HK; Seruga B; Knox JJ
Expert Opin Investig Drugs; 2009 Jun; 18(6):821-34. PubMed ID: 19453268
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer.
Gandhi KA; Joshi A; Mehta P; Gurjar M; Rane P; Sharma J; Patil A; Nookala M; Noronha V; Prabhash K; Gota V
Cancer Chemother Pharmacol; 2022 Jun; 89(6):751-759. PubMed ID: 35441269
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.
Ansari J; Fatima A; Fernando K; Collins S; James ND; Porfiri E
Oncol Rep; 2010 Aug; 24(2):507-10. PubMed ID: 20596640
[TBL] [Abstract][Full Text] [Related]
12. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
Shi HZ; Tian J; Chen X; Wang D; Li CL
Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
[TBL] [Abstract][Full Text] [Related]
13. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Houk BE; Bello CL; Poland B; Rosen LS; Demetri GD; Motzer RJ
Cancer Chemother Pharmacol; 2010 Jul; 66(2):357-71. PubMed ID: 19967539
[TBL] [Abstract][Full Text] [Related]
14. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS
Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090
[TBL] [Abstract][Full Text] [Related]
16. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.
Wolter P; Stefan C; Decallonne B; Dumez H; Bex M; Carmeliet P; Schöffski P
Br J Cancer; 2008 Aug; 99(3):448-54. PubMed ID: 18665181
[TBL] [Abstract][Full Text] [Related]
17. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
Chu D; Lacouture ME; Weiner E; Wu S
Clin Genitourin Cancer; 2009 Jan; 7(1):11-9. PubMed ID: 19213662
[TBL] [Abstract][Full Text] [Related]
18. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
[TBL] [Abstract][Full Text] [Related]
20. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
